Lumixyl® Topical Brightening System Demonstrates Effectiveness In Treating Melasma
Latest Publication from the Journal of Drugs in Dermatology Includes Diverse Set of Case Reports
WESTLAKE VILLAGE, Calif., May 17, 2012
WESTLAKE VILLAGE, Calif., May 17, 2012 /PRNewswire/ -- Envy Medical announced that the May 2012Journal of Drugs in Dermatology includes a report on case studies evaluating the effectiveness of the Lumixyl Topical Brightening System in the treatment of melasma.
Entitled "Treatment of Mild to Moderate Facial Melasma With The Lumixyl Topical Brightening System,"authorsBasil M. Hantash, MD, PhD, and Felipe Jimenez, PhD, Chief Scientific Officer of Envy Medical, Inc., examined four cases of mild to moderate melasma in three female and one male subjects, ages 30-47. Each volunteer was treated with the Lumixyl Topical Brightening System, which consists of an antioxidant cleanser, a brightening creme containing 0.01% decapeptide-12, a 20% glycolic acid lotion, and an SPF30 sunscreen.
After 12 to 24 weeks of use, investigators noted that the treatment protocol was well tolerated in all participants with only minor skin dryness observed during the first four weeks of using the Lumixyl System. Each had marked improvement in their respective melasma condition, and one had almost complete clearance after using the Lumixyl system for just six weeks. The authors conclude that the components of the Lumixyl System act synergistically to safely and effectively clear hyperpigmentation.
"The Lumixyl Topical Brightening System is an effective method for generating naturally brighter, more vibrant skin," explains Dr. Basil Hantash, MD, PhD, a board certified and Stanford-trained dermatologist and Vice-Chairman of the Board at Envy Medical, who also lead the Stanford University research team that developed the Lumixyl peptide technology. "This is yet another publication that illustrates the Lumixyl System's ability to clear melasma without the complications or irritations associated with hydroquinone-based products."
This case report follows the April 2012 publication of a 15 patient open-label study in the Journal of Cosmetic and Laser Therapy, which also examined the efficacy of the Lumixyl Topical Brightening System. That study revealed that the Lumixyl System was highly effective in treating hyperpigmentation without the irritation or other side effects associated with prescription hydroquinone. The article also notes that the Lumixyl regimen is safe for use by all skin types, including patients with skin of color and that it can be used by most patients for extended periods of time without concern.
The Lumixyl Topical Brightening System is sold through the physician dispensed channel, and was first commercially introduced in 2010. It has since experienced steady growth in popularity as a front-line therapy for diminishing the appearance of hyperpigmentation, promoting healthy skin function and encouraging an even skin-tone in over 30 countries worldwide. For more information, visit www.envymedical.com
ABOUT ENVY MEDICAL — Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company's lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion™ for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive licensor of skin brightening peptides including Lumixyl, developed at Stanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at www.envymedical.com.